Neurofibromatosis clinical trials

Please contact Hans Shuhaiber at and/or ( 312) 286 1059 for information about these Neurofibromatosis clinical trials.




NCT04924608– A Efficacy and Safety of Selumetinib in Adults With NF1 Who Have Symptomatic, Inoperable Plexiform Neurofibromas (KOMET) Phase III, Multicenter, International Study With a Parallel, Randomized, Double-blind, Placebo-controlled, 2 Arm Design to Assess the Efficacy and Safety of Selumetinib in Adult Participants With NF Who Have Symptomatic, Inoperable Plexiform  (KOMET). UF Health is only site in Florida. Sponsored through AstraZeneca.
NCT03962543– A MEK Inhibitor Mirdametinib (PD-0325901) in Patients With Neurofibromatosis Type 1 Associated Plexiform Neurofibromas


Phase 2b Trial of the MEK 1/2 Inhibitor (MEKi) PD-0325901 in Adult and Pediatric Patients With Neurofibromatosis Type 1 (NF1)-Associated Inoperable Plexiform Neurofibromas (PNs) That Are Causing Significant Morbidity. Sponsored with SpringWorks therapeutics
NCT04435665 A NFX-179 Topical Gel Treatment in Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF)


Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Phase 2a Study to Determine Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Activity of NFX-179 Gel in Subjects with Cutaneous Neurofibromas. Sponsored with Symbio LLC and NFlecion therapeutics.


To learn more see